<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885066</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000633338</org_study_id>
    <secondary_id>CALACASS-CAPERGEM</secondary_id>
    <secondary_id>ROCHE-CALACASS-CAPERGEM</secondary_id>
    <secondary_id>INCA-RECF0622</secondary_id>
    <secondary_id>EUDRACT-2007-005072-14</secondary_id>
    <nct_id>NCT00885066</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer</brief_title>
  <official_title>Phase I Study of Gemcitabine, Capecitabine, and Erlotinib Together in Advanced Pancreatic Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping
      them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth.

      PURPOSE: This phase I trial is studying the side effects and best dose of gemcitabine given
      together with capecitabine and erlotinib in treating patients with advanced pancreatic
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the maximum-tolerated dose of the combination of gemcitabine hydrochloride,
           capecitabine, and erlotinib hydrochloride in patients with advanced pancreatic cancer.

      Secondary

        -  Analyze the limiting toxicities according to CTC.

        -  Analyze the toxicity according to CTC.

        -  Determine the recommended dose.

        -  Determine the pharmacokinetic dosages of the three drugs.

        -  Analyze interactions between the drugs.

      OUTLINE: This is a multicenter study.

      Patients receive one course of chemotherapy comprising gemcitabine hydrochloride IV over 30
      minutes on days 1, 8, and 15, oral capecitabine twice daily on days 1-21, and oral erlotinib
      hydrochloride once daily on days 1-28.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical or laboratory toxicities as assessed by CTC</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>gemcitabine, capecitabine, erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>gemcitabine, capecitabine, erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <arm_group_label>gemcitabine, capecitabine, erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>gemcitabine, capecitabine, erlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas

               -  Advanced disease

          -  No standard curative therapy available

          -  Must have received prior first-line chemotherapy

          -  No brain metastasis

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Life expectancy ≥ 8 weeks

          -  ANC ≥ 1.5 x 10^9/ L

          -  Platelet count ≥ 130 x 10^9/ L

          -  Hemoglobin ≥ 10 g/dL

          -  Liver transaminases ≤ 1.5 times upper limit of normal (ULN) (≤ 5 times ULN in the
             presence of liver metastases)

          -  Bilirubin ≤ 1.5 times ULN

          -  Creatinine ≤ 130 mmol/L OR creatinine clearance &gt; 30 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No intolerance or hypersensitivity to any of the drugs being tested

          -  No history of interstitial lung disease

          -  No history of severe cardiac disease

          -  No serious uncontrolled infection

          -  No rare hereditary disorders, i.e., galactosemia, lactase deficiency, or malabsorption
             of glucose or galactose syndrome

          -  Must not be deprived of liberty or under guardianship

          -  Must not be on probation

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior erlotinib hydrochloride

          -  No concurrent potent inducers or inhibitors of cytochrome P450 or CYP3A4

          -  More than 14 days since participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Francois</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2009</study_first_submitted>
  <study_first_submitted_qc>April 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <last_update_submitted>February 8, 2015</last_update_submitted>
  <last_update_submitted_qc>February 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

